Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

620
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
620
Tumor Progression02:07

Tumor Progression

7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Measurement of Time-Dependent CP Violation in the Flavor-Changing Neutral-Current Decay B^{0}→K_{S}^{0}μ^{+}μ^{-}.

Physical review letters·2026
Same author

Measurement of the Top-Quark Production Cross Section and Charge Asymmetry at LHCb.

Physical review letters·2026
Same author

Searches for B^{0}→K^{+}π^{-}τ^{+}τ^{-} and B_{s}^{0}→K^{+}K^{-}τ^{+}τ^{-} Decays.

Physical review letters·2026
Same author

First Evidence of the B_{s}^{0}→K^{-}π^{+}γ Decay.

Physical review letters·2026
Same author

Precision Measurement of CP Violation and Branching Fractions in B^{±}→K_{S}^{0}h^{±} (h=π, K) Decays and Search for the Rare Decay B_{c}^{±}→K_{S}^{0}K^{±}.

Physical review letters·2026
Same author

First Observation of the B[over ¯]_{s}^{0}→Λ_{c}^{+}Λ[over ¯]_{c}^{-} Decay and Evidence for the B[over ¯]^{0}→Λ_{c}^{+}Λ[over ¯]_{c}^{-} Decay.

Physical review letters·2026

Related Experiment Video

Updated: Jan 5, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

614

[Synchronous multicentric osteosarcoma: treatment and prognostic factor analysis].

W F Liu1, Z Huang1, L H Gong2

  • 1Department of Orthopedic Oncology Surgery, Beijing Jishuitan Hospital, Peking University, Beijing 100035, China.

Zhonghua Yi Xue Za Zhi
|October 15, 2019
PubMed
Summary

Synchronous multicentric osteosarcoma (SMOS) has a poor prognosis and low survival rates. Standard chemotherapy is identified as the sole independent prognostic factor for improving survival in these patients.

Keywords:
ChemotherapyPrognosisSurgical treatmentSynchronous multicenter osteosarcoma

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

11.1K
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.6K

Related Experiment Videos

Last Updated: Jan 5, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

614
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

11.1K
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.6K

Area of Science:

  • Oncology
  • Orthopedic Surgery
  • Medical Research

Background:

  • Synchronous multicentric osteosarcoma (SMOS) is a rare variant of osteosarcoma.
  • Understanding its clinical outcomes and prognostic factors is crucial for patient management.

Purpose of the Study:

  • To identify the clinical outcomes of SMOS.
  • To determine the prognostic factors influencing survival in SMOS patients.

Main Methods:

  • Retrospective analysis of 2,602 conventional osteosarcoma patients.
  • Identification of 56 SMOS cases based on clinical, imaging, and pathological data.
  • Collection of epidemiological data, treatment details, and oncological results.
  • Statistical analysis including univariate and multivariate Cox regression.

Main Results:

  • SMOS patients had a 5-year survival rate of 10.4%.
  • Higher tumor load (≥5 sites) and lack of chemotherapy were associated with significantly lower survival rates.
  • Standard chemotherapy and surgical treatment were linked to improved survival.
  • Multivariate analysis identified standard chemotherapy as the only independent prognostic factor.

Conclusions:

  • SMOS is associated with a low survival rate and poor prognosis.
  • Chemotherapy and surgery can enhance survival outcomes.
  • Standard chemotherapy is a critical independent prognostic factor for SMOS.